Madison Asset Management LLC Takes $1.94 Million Position in GENMAB A/S/S $GMXAY

Madison Asset Management LLC purchased a new position in GENMAB A/S/S (OTCMKTS:GMXAY) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 70,781 shares of the company’s stock, valued at approximately $1,944,000.

GENMAB A/S/S Stock Performance

GMXAY opened at $31.94 on Friday. The business has a fifty day moving average of $28.32 and a 200 day moving average of $27.92. GENMAB A/S/S has a 52-week low of $12.10 and a 52-week high of $19.00.

About GENMAB A/S/S

Genmab A/S is a Denmark-based biotechnology company specializing in the creation and development of proprietary antibody therapeutics for the treatment of cancer and autoimmune diseases. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has focused on leveraging its innovative antibody platforms—such as DuoBody, HexaBody and DuoHexaBody—to generate next-generation therapies. The company’s expertise extends from early discovery through preclinical development, after which it partners with larger biopharmaceutical firms to advance candidates through clinical trials and commercialization.

Among Genmab’s most notable products is daratumumab, marketed under the brand name DARZALEX in collaboration with Janssen, which has become a leading monoclonal antibody for the treatment of multiple myeloma.